Our Portfolio.

AmpliMed's portfolio incorporates drugs with the potential to alter the course of several different types of cancer exploiting several different and novel mechanisms of action.

Both through our own chemists (the cyanoaziridine series, of which Amplimexon® is the lead product, the azonafide series, of which Amplizone™ is the lead product) and through the benzimidazole series (of which benzimate analogues are the lead compounds), we have access to at least 100 unique compounds. Our efforts are currently focused on Amplimexon® (imexon, inj.), which is currently in active Phase II development.

Amplimexon® has the benefits of orphan drug status for four cancer types (pancreas cancer, malignant melanoma, ovarian cancer and multiple myeloma), appears to be unaffected by the multi-drug resistance (MDR) pathway, has a novel mechanism of action, and can be combined at full dose with FDA-approved cytotoxic chemotherapeutics.



Human myeloma cells after treatment with imexon. The yellow dots in the cytoplasm depict the mitochondria, which are damaged by imexon, leading to tumor cell death.

Publications: Concerning Amplimexon®
Human myeloma cells after treatment with imexon. The yellow dots in the cytoplasm depict the mitochondria, which are damaged by imexon, leading to tumor cell death.


Publications: Concerning Amplimexon